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IMAGE-DRIVEN BIOPHYSICAL TUMOR GROWTH MODEL CALIBRATION
KLAUDIUS SCHEUFELE∗, SHASHANK SUBRAMANIAN †, ANDREAS MANG‡, GEORGE BIROS§, AND MIRIAM MEHL¶
Abstract. We present a novel formulation for the calibration of a biophysical tumor growth model from a single-time snapshot,
multiparametric Magnetic Resonance Imaging (MRI) scan of a glioblastoma patient. Tumor growth models are typically nonlinear
parabolic partial differential equations (PDEs). Thus, we have to generate a second snapshot to be able to extract significant infor-
mation from a single patient snapshot. We create this two-snapshot scenario as follows. We use an atlas (an average of several scans
of healthy individuals) as a substitute for an earlier, pretumor, MRI scan of the patient. Then, using the patient scan and the atlas,
we combine image-registration algorithms and parameter estimation algorithms to achieve a better estimate of the healthy patient
scan and the tumor growth parameters that are consistent with the data. Our scheme is based on our recent work (Scheufele et
al, “Biophysically constrained diffeomorphic image registration, Tumor growth, Atlas registration, Adjoint-based methods, Parallel algorithms”,
Computer Methods in Applied Mechanics and Engineering, 2018), but apply a different and novel scheme where the tumor growth simu-
lation in contrast to the previous work is executed in the patient brain domain and not in the atlas domain yielding more meaningful
patient-specific results. As a basis, we use a PDE-constrained optimization framework. We derive a modified Picard-iteration-type
solution strategy in which we alternate between registration and tumor parameter estimation in a new way. In addition, we consider
an `1 sparsity constraint on the initial condition for the tumor and integrate it with the new joint inversion scheme. We solve the
subproblems with a reduced-space, inexact Gauss-Newton-Krylov/quasi-Newton methods. We present results using real brain data
with synthetic tumor data that show that the new scheme reconstructs the tumor parameters in a more accurate and reliable way
compared to our earlier scheme.
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Picard iteration
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1. Introduction. Glioblastoma multiforme (GBM) tumor is a terminal primary brain cancer—the most
aggressive one. Biophysical models are increasingly used to help the analysis of GBM MRI scans for epi-
demiological studies but also for assisting clinical decision making [54,59], survival estimation, diagnosis,
and preoperative and treatment planing [14, 41, 47, 55]. The key step in integrating biophysical models
with clinical information is to calibrate them with patient MRI scans. After calibration, we can either use
the estimated parameters as biomarkers, or we can evolve the calibrated PDE to estimate short-term tumor
infiltration. Tumor growth models are typically nonlinear reaction-diffusion PDEs and their calibration
is challenging. Not only do we need to estimate reaction and diffusion parameters, but also the tumor
concentration, which is only partially (and implicitly) observed in the MRI scan. If we had an MRI scan
of the patient without tumor, we could solve an inverse problem for the initial condition, the reaction
and diffusivity parameters of the tumor. Unfortunately, a “healthy patient” MRI scan is rarely available.
To resolve this conundrum, Davatzikos’s group [41] pioneered the idea of using an MRI scan of another,
healthy, individual as a proxy for the tumor-free patient scan. In practice, we use a standardized average
brain of several individuals, also known as a statistical atlas. But it turns out that naively using such an
atlas would result in erroneous results. The second key idea addresses this by simultaneously using image
registration to deform the atlas towards to the patient scan as far as possible. In this paper, we present a
novel formulation of such a joint registration and inversion problem and a numerical solver scheme.
In the image registration problem, the goal is to estimate spatial point-correspondences between a tem-
plate image mT (the atlas) and a reference image mR (the patient scan). To solve the registration problem,
we use an optimal control formulation, in which we seek a (stationary) velocity field v (parameterizing
a deformation map y), such that the transported template image intensities match the intensities in the
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reference image, i.e., mT ◦ y ≈ mR. In the tumor inversion problem, we want to estimate tumor-growth
parameters (such as tumor origin, infiltration and proliferation rates) of our PDE model so that if we start
growing the tumor at t = 0 we match the partial tumor observations at t = 1. (The astute reader is prob-
ably wondering how do we know the time horizon. We don’t, but t = 1 is related to a non-dimensional
form of the tumor growth PDE.) We simultaneously solve for both v and the tumor parameters.
Let us try to explain the setting using a somewhat high-level notation. In our work we are not using
the original MRI scan intensities, but assume that we have segmentation labels describing different brain
tissue (white matter, gray matter etc.) distributions for both atlas and patient images. Let mA be the
healthy atlas labels and mD the patient labels (both vector functions in the unit cube in R3). Let T and R,
respectively, be abstract forward operators for a tumor simulation and registration mapping component.
T (m, p) takes a label image m without tumor and tumor model parameters p and creates a labeled image
that now has tumor labels in addition to the original healthy tissue labels (e.g., gray matter, white matter,
etc.). R(m, v) takes a label image m and a velocity v that parameterizes the deformation and creates a
deformed image.
Then, we can summarize the general idea of our previous Moving-Patient and the new Moving-Atlas
scheme by defining two optimization problems:
(1.1)
Moving-Patient (MP): minp,v‖R (T (mA, p), v)−mD‖,
Moving-Atlas (MA): minp,v‖T (R(mA, v), p)−mD‖.
Notice that the main difference is switching the order of the registration and the tumor operators; see
Fig. 1.1 for an illustration. This seemingly simple change has significant impact in the solution of this
problem. In [48, 49], we used the Moving-Patient scheme and only inverted for the tumor initial condi-
tion. Note that in MP, to evaluate the objective function, we first grow a tumor in the atlas and then
deform the patient image to match the resulting tumor-bearing atlas. As long as the tumor-bearing atlas
is topologically similar to the tumor-bearing patient brain, image registration can always yield good tu-
mor reconstruction, even with completely wrong tumor parameters. Thus this approach enables efficient
non-diffeomorphic registration between an atlas and a tumor-bearing patient, but is limited in terms of
meaningful tumor inversion.
In this paper, we propose the Moving Atlas scheme. To evaluate the objective function given, we first
deform the healthy atlas (using v) so that it matches the patient. Then we grow a tumor in the transformed
atlas. It turns out that the new formulation is more appropriate for the biophysical modeling since the
tumor growth takes place in images that resemble the actual patient.
Contributions. The main contributions of this paper are as follows:
(i) We present a new optimization problem formulation (Moving Atlas) for tumor growth model calibra-
tion based on patient individual single-snapshot data.
(ii) The new formulation prevents fitting of patient input data to a possibly poor tumor reconstruction.
The computed biophysical parameters “live” in the patient space, i.e., the tumor parameters are
estimated assuming tumor growth in (an approximation of) the healthy patient brain (as opposed to
the atlas brain for the former scheme). This renders the new scheme better for biophysical inversion.1
(iii) We derive a Picard-iteration-type solution scheme that alternates between the image registration and
the inverse tumor-growth problem.2
(iv) We enhance the tumor inversion component. The tumor solver used in [49] inverted for the tumor
initial condition only, penalized with an `2 constraint. In this paper, we use an `1 constraint (which
restricts the tumor to more plausible initial condition), and also invert for the diffusion parameter in
the tumor growth PDE (modeling tumor infiltration).
(v) We conduct numerical experiments to evaluate the nem scheme using synthetically grown tumor
data from real clinical brain imaging data. We demonstrate that the Moving Atlas scheme yields better
1The presented results are to be seen as a proof of concept for the developed methodology. To enable predictive capabilities, we
require a more complex tumor model.
2A modified objective function for the registration sub-component allows to fulfill the strongly coupled first order optimality
conditions of the joint optimization problem formulation
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Fig. 1.1: Schematic view of the Moving Patient and the (new) Moving Atlas scheme. The Moving Patient coupling-
scheme performs the tumor simulation (operator T ) (and parameter estimation) in a healthy atlas brain and warps the
patient anatomy and tumor labels towards the atlas space (operatorR) [48,49]. For the new Moving Atlas coupling-
scheme, we first compute an approximation of the actual healthy patient brain by warping the atlas anatomy labels
towards the patient (operator R) and perform the tumor simulation (operator T ) (and parameter estimation) in the
resulting approximation of the healthy brain geometry. This is critical to obtain patient specific tumor parameter
estimates (of, e.g., tumor origin, tumor cell migration rate, tumor cell proliferation rate) that may be of (future)
clinical relevance in decision making and treatment. Brain images modified from [14].
results in terms of the accuracy and robustness of tumor parameter reconstruction.3 For a synthetic
example, we showcase malfunction4 of the Moving Patient scheme, whereas the new Moving Atlas
scheme scheme yields good results.
Limitations. The reaction-diffusion tumor-growth model we consider is purely phenomenological.
Important biophysical, bio-mechanical and biochemical effects and phenomena such as mitosis, apoptosis,
chemotaxis, deformation of brain parenchyma (mass-effect), and the modeling of edema, necrosis, and
angiogenesis are neglected. It is, however, the most common model used for clinical analysis [5, 15, 17,
22, 53, 55]. The effect of tumor growth induced deformation of brain parenchyma is important and not
accounted for in our current model. This is ongoing work. Note that the main work here lies in the
enhancement of the tumor component. Integrating it in the coupled formaulation and the Picard iteration
is straight-forward due to our modular approach. The inverse tumor-growth problem with inversion for all
growth parameters is ill-posed. We have to introduce additional prior information. Currently, if we want
to invert for the proliferation rate ρ and the diffusion rate, we run the solver for multiple values of ρ and
compare the quality of reconstruction results. We do not account for uncertainties in input imaging data,
employed algorithms and solution approaches, and model parameters (such as tumor initial condition
and characteristic net cell migration into surrounding tissue). A Bayesian framework is subject to future
work; we currently invert for the maximum a posteriori estimate of the parameters. Our approach does
not directly process MRI data but requires prior segmentation of the imaging data. Note that reliably
integrating models with MRI is an open problem, since one needs to estimate cell-density from data or
link model output to intensities. Lastly, we emphasize that within this work we present a proof-of-concept
for a new, promising methodology; future work will include its application to real clinical data.
Related Work. One important application of biophysical models is to enable non-diffeomorphic image
registration. Classical image registration [39, 50] assumes that the input images (template and reference)
3For all considered test cases the tumor growth ground truth parameters are known, to allow for comparison of the respective
reconstruction accuracy.
4The patient input data is fitted to a poor reconstruction of the tumor in the atlas (due to large anatomical differences); conse-
quently, the target data is corrupted in the further course of the inversion.
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are topologically equivalent. But registering a healthy atlas (no tumor) to a tumor-bearing patient image
violates this assumption. We refer to this problem as the normal-to-abnormal registration. We refer to our
previous work in [49] for an extensive review in non-diffeomorphic image registration.
Here, we are interested in fitting models to patient-individual imaging data. Several groups have
tackled this problem using derivative-free optimization approaches [4, 20, 22, 29, 35, 38, 57, 58], or address
the parameter estimation problem within a derivative-free Bayesian framework [16, 24–27, 37, 45]. There
has been only limited work in the direction of PDE-constrained optimization for model-based image anal-
ysis [6,10,17,20,21,28,29,36,46]. Most of these approaches rely on longitudinal patient data. In particular,
they require knowledge of the healthy patient brain before tumor occurrence. To allow for model-inversion
based on single-snapshot data only, deformable inter-subject registration becomes necessary to artificially
generate a second snap-shot in time. Such a combination of registration and biophysical inversion has
been previously targeted in [14, 17, 41, 60–62]. The work in [41, 60–62], however, uses a purely mechanical
model for tumor progression and falls short in providing information about progression and infiltration
of cancerous cells into surrounding healthy tissue. In [2, 14, 17, 23], the authors propose a framework
for joint segmentation, registration and tumor modeling, which is very similar to our approach. In our
previous work [49], we significantly reduce the time-to-solution by employing second-order derivative in-
formation in conjunction with highly scalable and efficient numerics, improved algorithms and powerful
preconditioners. We eliminate the need for manual tumor seeding, and improve inter-subject registration
performance.
Outline. The outline of the paper is as follows: In §2 we present the mathematical formulation for the
Moving Atlas joint registration and biophysical inversion problem. We present the PDE-constrained opti-
mization problem and derive the first order optimality conditions in §2.1 and propose a Picard-iteration-
type solution strategy, outlined in §2.2. Details on continuation schemes, adaptivity and convergence
criteria are given in §2.3. More details on the two main sub-components, diffeomorphic medical image
registration and biophysical tumor-growth inversion are summarized in §3. In §4, we perform numerical
experiments to analyze our scheme, and compare it to the Moving Patient scheme [49].
2. Formulation and Picard Iteration for the Moving Atlas Coupled Problem. To apply tumor inver-
sion and image registration in a joint approach, we consider an optimal control formulation, which results
in a PDE-constrained, nonlinear optimization problem. In this section, we present the new Moving Atlas
formulation along with an iterative fixed-point coupling scheme. This scheme allows us to solve the joint
optimization problem based on two separate components: a tumor-growth inversion solver and a mod-
ified diffeomorphic image registration component. Before presenting the formulation and the iterative
solver, we shortly introduce the notation we are going to use throughout the paper.
Notation. mX(x, t) ∈ [0, 1], (x, t) ∈ Ω× [0, 1], with X ∈ {WM, GM, CSF} represents probability maps of
different brain tissue types, namely, white matter (WM), gray matter (GM), and cerebrospinal fluid (CSF;
which includes ventricles). The probability maps for each tissue label are computed from (segmented)
MR imaging data in a pre-processing step. In the following, we refer to mX(x, t) as anatomy labels.
Ω = [0, 2pi]3 denotes the normalized spatial domain. We gather these probability maps in a space-time
vector field
(2.1) m(x, t) = (mi(x, t))i=WM,GM,CSF ∈ R3
The normalized tumor cell concentration c : ΩB × [0, 1] → [0, 1], (x, t) 7→ c(x, t) (tumor map) is given as
a fourth field and interpreted as probability map for cancerous tissue. ΩB ⊂ Ω = [0, 2pi)3 is embedded5
in the simulation domain Ω and denotes the domain occupied by brain tissue; it is bounded by the
skull. All anatomy and tumor labels evolve in space and time. To simplify notation, we introduce the
space-time domain U := Ω× (0, 1], and U¯ := Ω× [0, 1). We omit the spatial dependency, and indicate
temporal evolution by the pseudo time tR ∈ [0, 1] for the advection problem of the registration, and the
normalized time tT ∈ [0, 1] for tumor growth, cf. Tab. 2.1. To judge the proximity of the predicted state
of our mathematical model to the observed data mD, cD, we define the `2-distance measures Dc and Dm
(see Tab. 2.1), which drive the optimization process.
5We use a penalty approach to discretize the tumor equations in Ω and approximate the Neumann boundary conditions on ∂ΩB.
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Table 2.1: Notation for the Moving Atlas joint tumor inversion and image registration formulation: m denotes the
vector of anatomy labels (probability maps for white matter (WM), gray matter (GM) and cerebrospinal fluid (CSF))
defining the brain geometry, and c denotes a probability map for tumor (TU). Subscripts A and P indicate variables
in the atlas and patient space, respectively. Anatomy labels and tumor label with subscript D denote the patient
input imaging data (after prepossessing). The fields evolve in time and space; anatomy labels m for brain tissue
evolve along a pseudo-time tR ∈ [0, 1] associated to registration, and tumor labels evolve along the (normalized)
time tT ∈ [0, 1] of tumor growth. The integration of a simulated tumor map c(1) into healthy brain tissue m is
indicated by m′ and modeled via the formula m′ = m(1− c(1)). To judge the proximity of the predicted state of our
mathematical model to the observed data mD, and cD, we define the `2-distance measures Dc and Dm.
healthy atlas brain (input) mA
mP(0)
R
mP(1)
c(0)
T m′P(1)
c(1)
tR = 0 tR = 1
tT = 0 tT = 1
Atlas
mA
Patient
mD, cD
patient brain with tumor (input; target data) mD
patient tumor (input; target data) cD
healthy patient brain mP(1)
tumor initial condition c(0)
simulated tumor c(1)
approximated patient brain m′P(1)
`2-misfit tumor Dc [c1, c2] := 12‖c1 − c2‖2L2(Ω)
`2-misfit anatomy labels Dm [m1, m2] := 12‖m1 −m2‖2L2(Ω)3
2.1. Moving Atlas Coupled Formulation. The Moving Atlas coupled problem formulation is given by
the minimization problem
min
v,p,k f ,w
Dc[c(1), cD] +Dm[mP(1)(1− c(1)), mD] + S [p, v, w]
subject to
T : (tumor forward op.) ∂tc− div k(mP(1))∇c− f (c, ρ(mP(1))) = 0 in U,(2.2a)
Φ(mP(1))p = c(0) in Ω,(2.2b)
R : (registration advection op.) ∂tmP +∇mP · v = 0 in U¯,(2.2c)
mA = mP(0) in Ω,(2.2d)
div v = w in U,(2.2e)
That is, we seek parameters and space time fields (v, p, k f , w), such that the predicted state of our model
becomes similar to the observed data. The distance between data and predicted state is quantified by the
two `2-distance measures Dc[c(1), cD] and Dm[mP(1)(1− c(1)), mD]. Dc[c(1), cD] measures the discrep-
ancy between the simulated tumor c(1) computed from (2.2a)–(2.2b) in the approximated patient space
and the input tumor data cD. Dm[mP(1)(1− c(1)), mD] quantifies the discrepancy between the patient’s
anatomy labels and the warped-to-patient atlas anatomy labels in regions not affected by the tumor6
computed from (2.2c)–(2.2e)). S [p, v, w] := βpSp[p] + βvSv[v] + βwSw[w] is a regularization term.
To simulate tumor-growth over time, we use a diffusion-reaction model with diffusion tensor k and
a logistic reaction term f (c, ρ) = ρc(1− c) with reaction rate ρ. For the tumor initial conditions, we use
a parametrization Φp, i.e., c(0) lives in an np-dimensional space spanned by Gaussian basis functions
(p ∈ Rnp , Φp := ∑npi=1 Φi pi). Within CSF, the Gaussians are set to zero to prevent spurious diffusion of
cancerous cells into CSF. We model the diffusion and reaction coefficient as
(2.3) k(m) := k f
3
∑
i=1
kimi I = kmI and ρ(m) := ρ f
3
∑
i=1
ρimi = ρm
with k = (k1k f , k2k f , k3k f )T and ρ = (ρ1ρ f , ρ2ρ f , ρ3ρ f )T , i.e., both diffusion and reaction parameters vary
in space depending on the value of the anatomy labels m describing the brain geometry. For simplicity,
6The simulated pathology is embedded into the advected atlas anatomy labels when caculating the registration misfit. This can
be seen as a “masking” of the tumor region, i.e., the registration does not alter the tumor concentration nor the discrepancy measure
Dc.
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we only consider isotropic diffusion7. To regularize the tumor growth initial condition parametrization,
we use combinations of `1- and `2-regularization, i.e.,
(2.4) S1p[p] =
1
2
‖p‖2L1(Ω) and S2p[p] =
1
2
‖p‖2W(Ω) :=
pn
∑
i=1
wi · p2i ,
where βp > 0 is the regularization parameter and ‖ · ‖W(Ω) is a weighted `2-norm. For more details on
how we switch between the two penalty terms in the solver algorithm, see §2.3.
For image registration, we use an advection model with a stationary velocity field v. The image
registration velocity is regularized via the H1 Sobolev semi-norm:
(2.5) Sv[v] = 12‖v‖
2
H1(Ω) =
1
2
∫
Ω
3
∑
i=1
|∇vi(x)|2 dΩ.
Sw[w] = ‖w‖L2(Ω) is a regularization term for w = div v, which allows us to control volume change. We
use periodic boundary conditions on ∂Ω.
Optimality Conditions. As a general optimization approach, we use the method of Lagrange multipli-
ers. Taking variations yields the strong form of the first order optimality conditions:
tum., state ∂tc− div k(mP(1))∇c− f (c, ρ(mP(1))) = 0 in U,(2.6a)
c(0)−Φ(mP(1))p = 0 in Ω,(2.6b)
tum., adj. −∂tα− div k(mP(1))∇α+ ∂c f ?(c, ρ(mP(1)))α = 0 in U¯,(2.6c)
cD − c(1) + (mP(1))T(mP(1)(1− c(1))−mD)− α(1) = 0 in Ω,(2.6d)
reg., state ∂tmP +∇mPv = 0 in U¯,(2.6e)
mP(0)−mA = 0 in Ω,(2.6f)
reg., adj. −∂tλ− div (λ⊗ v) = 0 in U¯,(2.6g)
(c(1)− 1)(mP(1)(1− c(1))−mD) + ∂mP(1)Φ(p)α(0)−(2.6h) ∫ 1
0
(∇c)T∇α ∂mP(1)k?(mP(1)) + ∂mP(1) f ?(c, ρ(mP(1)))α dt− λ(1) = 0 in Ω,
tum., inv. βp∇pSp[p]−ΦTα(0) = 0 in Ω,(2.6i) ∫ 1
0
∫
Ω
mP(1)
(
(∇c)T∇α
)
dx dt = 0 in Ω,(2.6j)
reg., inv. βv∇vSv[v] +K[
∫ 1
0
(∇mP)Tλ dt] = 0 in Ω,(2.6k)
with adjoint variables α, λ, ν associated to the state variables c(1), mP, and mP(1). We eliminate w from
the optimization problem and use the resulting operator K in (2.6k). For div v = w = 0, K would be the
Leary projection K(u) := u+∇ ∇−1div u; for a non-zero w, the projection operator becomes slightly more
involved; we refer to [30, 31] for additional details. The gradients of the diffusion and reaction terms in
(2.6h) with respect to mP(1) can be derived from (2.3), and are given by:
∂mP(1)k = k¯ = k f (k1, k2, 0) and ∂mP(1) f = ρmP(1)(1− 2c(1)).(2.7)
Discussion. We summarize the advantages of the moving atlas scheme over the previously used
moving patient scheme [49]: (i) image registration operates on the brain anatomy only such that the
tumor solver is forced to actually produce a biophysically more meaningful8 tumor that is similar to
the observed patient tumor. (ii) Tumor growth parameters, i.e., p and k f , are estimated directly in an
7Note, that our approach can be generalized in a straight-forward way to general diffusion tensors
8Assuming a biophysical tumor progression model which accurately reflects the physiological processes; the model used here
does not fulfill this assumption.
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approximation of the patient brain such that their quality does not strongly deteriorate with differences
between the atlas and the patient brain. This comes at a price, for which we account for by employing
suitable solver strategies presented in §3: (a) the decomposition of the moving atlas formulation into
tumor and registration components requires modifications of the registration formulation as shown in
§2.2, (b) exploiting the full potential of the moving atlas scheme requires sparse localization of the tumor
initial condition, encouraged by an `1-regularization in the tumor component as outlined in §3.1 (cf.
also [48, 52]).
2.2. Picard Iteration Scheme. We solve the optimization problem by iterating over the registration
velocity v, the tumor growth initial guess parametrization p and (if switched on) the diffusion coefficient
k f . We use a superscript j to mark variables associated with the jth Picard iteration. Each Picard iteration
is decomposed two into sub-steps:
(1) Solve inverse tumor problem, i.e., given vj solve for (pj+1, kj+1f ) such that
(2.8) (pj+1, kj+1f ) = arg min
p,k f
Dc[c(1), cD] +Dm[mP(1)j(1− c(1)), mD] + βpSp[p]︸ ︷︷ ︸
=: JT
subject to the tumor forward problem (2.2a) and (2.2b) for the healthy patient anatomy mP(1) =
mP(1)j kept fixed (result of the previous Picard iteration or initial guess). This means, we fulfill the
first order optimality conditions (2.6a)–(2.6d), (2.6i) and (2.6j) for mP(1) = mP(1)j. Aside from new
iterates for p and k f , this step yields a new simulated tumor c(1)j+1 and tumor adjoint αj+1.
(2) Solve modified registration problem, i.e., given (pj+1, kj+1f ), solve for v
j+1 such that
(2.9) (vj+1, wj+1) = arg min
v,w
Dm[mP(1)(1− c(1)j+1), mD] +
∫
Ω
qTmP(1) dx + βvSv[v] + βwSw[w]
subject to the image advection problem (2.2c)–(2.2e). q = (q1, q2, q3)T is defined as
q(x) =
∫ 1
0
k((∇c(1)j+1)T∇αj+1) + ρc(1)j+1(1− c(1)j+1)αj+1 dt.
(3) iterate until convergence.
The particular modification of (2.9) by introducing the term
∫
Ω q
TmP(1) dx ensures that the registra-
tion problem reproduces (2.6e) – (2.6h) and (2.6) as first order optimality conditions. Note that we freeze
the variables c(1), and α from the previous iteration, i.e., neglect the indirect impact of the registration ve-
locity v on c(1) and α via changes in mP(1). Besides new iterates for v, the registration step also provides a
new approximation mP(1)j+1 of the healthy patient brain. The converged solution of the respective Picard
or fixed-point iteration fulfills all first order optimality conditions of (2.2) with the exception of (2.6h). For
the latter, the term ∂mP(1)Φ(p)α(0) is neglected and not enforced explicitly. We found experimentally, that
our scheme works well and produces satisfying results despite the simplification.
2.3. Adaptivity and Convergence Criteria. In our Picard scheme, we use several strategies to control
convergence and to adapt the tumor and image registration regularization over the Picard iterations.
For the tumor solver, the regularization term βpSp[p] is used to attain better conditioning, but also
to encourage sparse localization of the initial condition. Thus, we use Sp[p] = 1/2‖p‖2L1(Ω) to compute
a sparse solution of the initial condition and switch to a weighted `2-regularization Sp[p] = ‖p‖2W(Ω) =
1/2∑
pn
i=1 wi · p2i in a second phase of the tumor inversion solver, where the weights wi are calculated
according to
wi =
{
wlarge if |p`1i | < τS‖p‖L∞(Ω)
wsmall otherwise.
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Here, τS is a user defined tolerance. The `2-phase uses p`1 achieved in the `1-phase as initial approxima-
tion. In the `1-phase we invert for p only and keep the diffusivity k f (estimated in the `2-phase) fixed;9
initially, we start with k f = 0. For more details on numerics of the tumor inversion solver, we refer to [49].
For the registration solver, convergence and robustness are improved by regularization. We perform
a parameter continuation. That is, we start with a large value βinitv and subsequently reduce βv by a
factor of ten after each Picard iteration until we reach the prescribed value βfinalv . Image registration
calculates solutions and possibly increases βv internally based on a check of lower admissible bounds
for the determinant of the deformation gradient. The deviation of the determinant of the deformation
gradient from one indicates local volume changes (expansion for a value larger then one and contraction
for a value smaller then one; see [31, 49] for more details).
As a stopping criterion for the Picard iterations, we consider a mixed criterion that is fulfilled either
if we reach βfinalv or if the image registration fails due to violation of the user defined lower bound on the
determinant of the deformation gradient. We always execute two Picard iterations with the final βfinalv .
For both tumor inversion and image registration, we use fixed tolerances for the norm of the reduced
gradients as given in (2.6i), (2.6j), and (2.6k), respectively. Note that we use norms relative to the gradient
norm at the beginning of the first Picard iteration for all gradients. We combine these gradient toler-
ances with a prescribed maximal number of Newton iterations for the reduced space KKT systems (see
also [49]).
3. Numerical Methods for Tumor Inversion and Image Registration. In this section, we shortly
describe the numerical and algorithmic features of the tumor and the image registration solvers. We give
only a brief summary along with references to previous publications since these methods have not been
changed from our previous work.
3.1. Regularization and Nonlinear Solver Components for Tumor Inversion. The tumor inversion
problem is solved based on an optimize-then-discretize approach. To solve the respective system of op-
timality conditions, we use different solvers for `1 or weighted `2-regularization, respectively. For `1-
regularization, the General Iterative Shrinkage Thresholding (GIST) [13] is applied. In every iteration, it
determines a solution pk+1 close to the result pksd of a gradient descent step in the direction ∇Dc(c(1), cD)
with step length αk:
pk+1 = arg min
p
1
2
‖p− pksd‖2L2(Ω) + αk
βp
2
‖p‖L1(Ω), and(3.1a)
pksd = p
k − αk∇Dc(c(1), cD)(3.1b)
To determine the step length αk, we use Armijo line search. For `1-regularization, we find the analytical
solution:
pk+1 = sign(pksd)max(0, |pksd| − αkβp).(3.1c)
The stopping criteria are given by
|JT(pk+1)−JT(pk)| < τJ(1+ JT(p0))(3.2a)
‖pk+1 − pk‖L∞(Ω) < √τJ(1+ ‖pk+1||L∞(Ω)),(3.2b)
where JT is the objective function of the tumor inversion problem (2.8), and τJ > 0 is a user defined
tolerance. We perform parameter continuation in βp to estimate its value. We start with a large βp,
bounded by ‖∇Dc(c(1), cD)‖L∞(Ω) and perform a binary search in subsequent GIST iterations based on
the Hoyer sparsity measure [19], Hs(p) ∈ [0, 1]:
(3.3) Hs(p) =
np − ‖p‖L1(Ω)/‖p‖L∞(Ω)
np − 1
9We found experimentally, that diffusion inversion in the `1-phase has vanishing impact on the proposed sparsity of the solution,
and the `2 estimation for k f is better.
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where np is the dimensionality of p. Solutions with larger values of Hs feature higher sparsity, i.e., have
less non-zero entries. We use a tolerance of 0.95 to identify sparse solutions. If the sparsity is large enough
(larger than the tolerance), we search for a smaller regularization parameter and, alternatively, increase it
if the sparsity is insufficient. GIST features slow first order convergence, which is, however, acceptable for
our purpose as only a rough estimate for c(0) is to be calculated with `1-regularization.
In the `2-phase, we employ a reduced space method. This means that we assume the state and adjoint
equations to be fulfilled exactly; they can be eliminated from the KKT system. For the tumor inversion
solver, the reduced gradients are calculated based on the current iterates for p and k f as follows: (i) solve
the state equations (2.6a) – (2.6b), (ii) use the result to solve the adjoint equations (2.6c) – (2.6d), (iii) insert
the result in (2.6i) – (2.6j) to calculate the reduced gradient with respect to p and k f .
As a solver for the reduced KKT system, we use a quasi-Newton approach (LBFGS, [44, p. 135ff])
yielding a matrix-free approximation of the matrix-vector product of the gradient with the respective
inverse Hessian and, thus, making an inner linear solver obsolete. We use More´-Thuente line-search [42]
for globalization.10 The `2-phase is terminated when the relative change of the norm of the reduced
gradient is below a user defined threshold opttolT > 0. The reference gradient is the gradient obtained
for the zero initial guess, p0.
3.2. Nonlinear Solver Components for Image Registration. We use an optimize-then-discretize ap-
proach for the image registration solver [34]. We employ a reduced space method: The current iterate for
the velocity v is used to (i) solve the state equations (2.6e) – (2.6f) (forward advection), (ii) use the result to
solve the adjoint equations (2.6g) – (2.6h), (iii) insert the result in (2.6k) to calculate the reduced gradient.
We use a Newton-Krylov approach with an inexact Gauss-Newton linearization and a matrix-free
PCG method as inner linear solver (see [11, 30–33] for more details) to compute the search direction.
For the convergence of the optimizer, we use a combination of the relative change of (i) the norm of
the gradient in (2.6k), (ii) the objective in (2.9) and (iii) the control variable v, all controlled by a single
parameter opttolR > 0, as a stopping criterion. More details on the stopping conditions can be found
in [30, 40]; see [12, 305 ff.] for a discussion. For the inner PCG solver, we perform inexact solves [7, 8]
with a tolerance that is proportional to the norm of the reduced gradient of our problem. This prevents
over-solving of the Hessian system if far from the optimum (large gradient norm). See also [44, p. 165ff.]
for details. We use Armijo line-search for globalization.
For both tumor inversion and registration solver, we specify a maximum number (maxitN,T / maxitN,R)
of Newton, a maximum number (maxitK,T / maxitK,R) of Krylov iterations, and a lower bound of 1E−6 for
the absolute norm of the gradient as a safeguard against a prohibitively high number of iterations.
3.3. Discretization in Space and Time for the State and Adjoint Equations. For all state and ad-
joint equations in (2.6), we use the following numerical ingredients that have been published in more
detail in [1, 10, 11, 30–33]: (i) spectral elements for spatial discretization combined with a regular mesh;
(ii) 3D Fourier transforms to compute spatial derivatives; (iii) an unconditionally stable semi-Lagrangian
time-stepping scheme to avoid stability issues and small time-steps for image advection; (iv) an approxi-
mation of boundary conditions for the tumor equations at the brain surface based on a penalty approach
combined with periodic boundary conditions at the boundary of the overall domain Ω¯ = [0, 2pi]3; (v) an
unconditionally stable, second order Strang-splitting approach [18, 51] with analytical solution of the re-
action terms and an implicit Crank-Nicholson method for the diffusion terms in the tumor equations.
4. Numerical Results. The experiments serve as a proof of concept for the newly developed joint reg-
istration and biophysical inversion strategy (Moving Atlas) and demonstrate that the previously introduced
moving patient scheme [49] can fail dramatically in terms of both tumor reconstruction and inversion for
initial conditions and tumor growth parameters. We quantitatively and qualitatively compare the new
Moving Atlas strategy to the Moving Patient with an emphasis on model inversion and parameter esti-
mation and address the scheme’s eligibility to recover true model parameters. This is an important step
towards reconstruction of meaningful biophysical characteristics. We consider the following classes of test
cases:
10Note that we do not use line-search in the outer Picard iterations.
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SYN – Synthetic Brain. This first academic test case shows that the moving patient scheme can dra-
matically fail in terms of biophysical inversion. More precisely, we demonstrate that the moving patient
scheme yields largely wrong reconstruction of the tumor, the tumor initial condition, and the diffusion
coefficient. We use two simple elliptical anatomies consisting of white matter and gray matter only for
atlas and healthy patient brain, respectively, and grow a tumor with known diffusion and reaction pa-
rameters in the patient anatomy. The resulting pathologic patient brain serves as target input data for our
joint inversion approach. In order to achieve significant results, we create a case with large inter-subject
differences between atlas and patient anatomy.
STRV – Synthetic Tumor, Real Velocity. This second class of test cases is based on real brain geometries
and serves as a means to examine the potential of the moving atlas formulation for biophysical inversion
in realistic geometries, i.e, to examine the quality of reconstruction for the known ground truth initial
conditions, k f and healthy patient geometry. We use two different real healthy brain geometries and grow
a synthetic tumor in one of them, which we use as the patient brain. The second healthy brain serves as
a normal brain template (atlas brain). In contrast to real patient tumors, in this case we know the ground
truth for tumor initial conditions, diffusion coefficient k f and healthy patient geometry. Note that we do
not know the ground truth for the registration velocity v.
In our test cases, we compare three different solution strategies:
I. Tumor Standalone (T). For the tumor standalone solution, the inversion is carried out assuming a
statistical atlas brain geometry as healthy patient brain. No inter-subject registration is applied. The error
is a function of the inter-subject variability between atlas and patient brain.
II. The Joint Registration and Biophysical Inversion Moving Patient Scheme (MP). The Moving Patient scheme
presented in [49] exhibits some inherent shortcomings with respect to the suitability for biophysical inver-
sion and model calibration. The registration may fit the input data to a poor tumor reconstruction. We
use the method described in [49] enhanced with a sparsity constraint for the tumor inversion solver §3.1.
III. The Joint Registration and Biophysical Inversion Moving Atlas Scheme (MA). The Moving Atlas scheme
presented in this work is designed to remedy some of the shortcomings of the Moving Patient scheme.
In the following, we shortly describe data and parameters for the experiments in §4.1 as well as the
hardware used and the general setup in §4.2. We introduce performance measures used in the evaluation
of our numerical results in §4.3. In §4.4, and §4.5 we show results for the two classes of test cases.
4.1. Data and Parameters. We use a common data basis for brain geometries as well as some fixed
parameter settings for all test cases as described below.
Brain Imaging Data. For the STRV cases, we use normal brain MR imaging data obtained at the
Perelman School of Medicine at the University of Pennsylvania. The three-dimensional imaging data have
an image resolution of 2563 voxels. We use binary segmentations of MRI scans for white matter (WM),
gray matter (GM), and cerebrospinal fluid with ventricles (CSF). In a pre-processing step, these labels are
smoothed and rescaled to probability maps, i.e, values between zero and one. To ensure partition of unity
across all anatomy labels for each x in Ω, we introduce a fourth probability map for background based on
∀x ∈ Ω : c(·,1)(x) +
4
∑
i=4
m(·,1)i (x)
!
= 1.
Common Model and Numerical Parameters. The tumor model and solver parameters are summarized
in Tab. 4.1. The solver parameters are based on experiments. We briefly discuss some of the more involved
choices: For the parametrization of the tumor initial condition, we select a regular grid of np Gaussian
basis functions with a variable standard variation σ ∈ {2pi/30, 2pi/64} and a grid spacing of δ = 1.5σ around
the center of mass of the tumor. The number np is chosen a priori on a case-by-case basis, such that the
pathological domain is covered sufficiently.
For all experiments, we consider tumor growth only in white matter (k1 = 1; ρ1 = 1), and, conse-
quently, set the characteristic diffusivity and net cell proliferation in gray matter and CSF to zero, i.e.,
k2 = k3 = 0, and ρ2 = ρ3 = 0. To grow the synthetic tumor, we choose ρ?f = 15 as cell proliferation
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rate (reaction coefficient), and k?f = 1E−1 as rate of cell migration into surrounding tissue (diffusion
coefficient), respectively. For the tumor evolution simulation, we choose a time step of ∆t = 0.01 and
various time horizons T ∈ {0.16, 0.32, 0.44}. The regularization parameter βp for the `2-regularized in-
verse tumor problem has been determined experimentally from an L-curve study similar to [10], using
np = 125 Gaussian basis functions and an image resolution of n = 1283. We fix the relation σ/δ = 1.5 for
the spacing of the Gaussian basis functions11. The lower bound β f inalv on the regularization parameter βv
has been determined based on extensive numerical experiments for different synthetic and real brain data
sets [31, 32]. By experimental analysis we found that reducing the regularization weight by a factor of 10
in every Picard-iteration is sufficient12. For the optimizer, we use tolerances of opttolR = opttolT = 1E−3
for registration and tumor inversion, respectively13. Further reduction of the gradient did not improve
the final reconstruction quality, since the overall error is bound by an O(1E− 3) error introduced by the
solution of the hyperbolic advection problem (cf. [49]). To prevent prohibitively large runtimes, we define
upper bounds on the number of Newton (and Krylov) iterations.
Table 4.1: Summary of common parameters used in all test cases. We report values of the following parameters: n
denotes the image resolution with ni, i = 1, 2, 3; np is the number of Gaussian for the parametrization of the tumor
initial condition, σ is the standard deviation of the associated Gaussian basis functions (and varies throughout test
cases), δ denotes the spacing in between centers of adjacent Gaussians; k1, k2 and k3 are the characteristic diffusion
parameters for WM, GM, and CSF, k f the overall scaling parameter for the isotropic part of the diffusion coefficient
for net migration of cancerous cells into surrounding tissue; ρ1, ρ2, and ρ3 are the characteristic reaction factors
for WM, GM, and CSF, ρ f is the overall reaction scaling factor; opttolR, opttolT are the convergence tolerances for
registration and tumor inversion; maxiti = (maxiti,N , maxiti,K) denotes the maximum number of Newton iterations
and Krylov iterations (for the KKT system) for the tumor inversion (i = T) and registration (i = R), respectively;
βp is the regularization parameter for the tumor inversion; βinitv and β
f inal
v are the initial and final values for the
β-continuation scheme, applied in image registration; ε∇ is the bound on the variation of the deformation gradient
det(∇y) used in the continuation scheme.
Description Parameter(s) Value(s)
image resolution n = n1 · n2 · n3 ni = 128
tumor initial condition parametrization np, σ, δ {125, 343}, { 2pi30 , 2pi64 }, 1.5
tumor growth characteristic cell diffusivity k¯ = k?f (k1, k2, k3)
T 0.1 · (1, 0, 0)T
tumor growth characteristic net cell proliferation ρ¯ = ρ?f (ρ1, ρ2, ρ3)
T 15 · (1, 0, 0)T
optimizer tolerances opttolR, opttolT 1E−3, 1E−3
maximum Newton / Krylov iterations, tumor inversion maxitT = (maxitT,N , maxitT,K) (50,−)
maximum Newton / Krylov iterations, registration maxitR = (maxitR,N , maxitR,K) (50, 80)
tumor inversion regularization parameter βp 1E−4
registration regularization parameter (continuation) βinitv , β
f inal
v 1, 1E−4
bound on local volume change (variation det(∇y)) ε∇ 1E−2
4.2. Hardware and Setup. All numerical experiments were executed on the supercomputer HazelHen
at the High Performance Computing Center HLRS in Stuttgart (www.hlrs.de), a Cray XC40 system with
a peak performance of 7.42 Petaflops comprising 7, 712 nodes with Xeon E5-2680 v3 processors and 24
cores on two sockets and 128 GB memory per node. Our SIBIA framework is written in C++ and uses MPI
for parallelism. It is compiled using the Intel 17 compiler. We use PETSc’s implementations for linear
algebra operations and PETSc’s TAO package for the nonlinear optimization [3, 43], AccFFT for Fourier
transforms [9, 10], and PnetCDF for I/O [56]. We use 3 nodes with 64 MPI tasks for (down-sampled) data
sizes of size ni = 128, i = 1, 2, 3 for all runs reported in this study.
11This leads to an invariant condition number of ΦTΦ for the corresponding interpolation problem for varying standard variations
σ, i.e., width of the Gaussians.
12Using a smaller reduction or more Picard-iterations per fixed regularization weight did not improve the overall result.
13Note that, in combination with the applied stopping conditions, this results in a required relative gradient of 1E−3 for the
tumor inversion, but a gradient reduction of only about two orders of magnitude for the registration.
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4.3. Performance Metrics. The task of our numerical experiments is to assess (i) the convergence to-
wards solutions with low mismatch between the prediction of our model in (2.2a)–(2.2e) and the observed
patient input data, both in the brain geometry m and the tumor c (for all test cases), (ii) the reconstruction
quality for the (in practice inaccessible) healthy patient brain14 as a direct output of the moving atlas for-
mulation, (iii) the quality of inversion for the biophysical parameters, i.e., tumor growth initial conditions
and diffusion coefficient, in terms of correctness of the parameters compared to the known ground truth.
We report all performance measures in the patient space, i.e., with respect to the patient anatomy and
not the atlas anatomy, since the patient space is the relevant space from an applications point of view.
We use the following metrics: We measure the relative mismatch/residual between patient anatomy and
reconstructed anatomy, between the reconstructed healthy patient anatomy and the ground truth, and
between patient tumor and simulated tumor in the patient domain (compare Fig. 2.1):
µB,L2 :=
‖m′P(1)−mD‖L2(Ω)3
‖mA−mD‖L2(Ω)3
, µB0,L2 :=
‖mP(1)−m?P(1)‖L2(Ω)3
‖mA−m?P(1)‖L2(Ω)3
, µT,L2 :=
‖c(1)−cD‖L2(Ω)3
‖cD‖L2(Ω)3
where m?P(1) denotes the ground truth healthy patient brain. Based on the cardinality | · | of a set and a
selection function H with threshold 0.5, i.e.,
H(u) := {ui ≥ 0.5},
we calculate Dice coefficients for the individual label maps associated with the anatomy labels for l ∈
{WM, GM, CSF} and their average across labels for the patient and the atlas anatomy
DICEl,B := 2
|H(mP,l(1))∩H(mD,l)|
|H(mA,l)|+|H(mD,l)| , DICEB = ∑
3
l=1 DICEl,B/3;
Analoguously, we report values for the Dice coefficient computed for the healthy patient geometry, de-
noted by DICEB0 , and for the anatomy label of the tumor, denoted by DICET . To monitor convergence
of the Picard iterations, we report the relative value of an approximation to the gradient for the coupled
problem (see §2.1) for the final iteration k:
‖g‖rel := ‖g j‖L2(Ω)/‖g0‖L2(Ω).
where g j is an approximation to the gradient of the coupled optimization problem (2.2) (given by (2.6i) –
(2.6k)) after the ith Picard iteration and g0 the corresponding approximate gradient for the initial guess.
The gradient is only approximate, since we neglect the term ∂mP(1)Φ(p)α(0) in the final condition (2.6h)
of the adjoint equation for the registration problem. This term is guaranteed to be small if the norm of the
remaining gradient is small as the latter requires α(0) and the change in the estimated patient geometry
to be small. Finally, we calculate the relative `2-error for the initial condition:
ec0,L2 := ‖Φp? − c(0)‖L2(Ω)/‖Φp?‖L2(Ω),
where c(0) = Φp and Φp? denotes the parametrization of the ground truth tumor initial condition.
4.4. Results for SYN – Synthetic Brain. This first, purely synthetic experiment uses two fairly dif-
ferent, very simplistic anatomies for the atlas and patient brain and an artificially grown tumor in one of
them (called the patient brain).
Purpose. This case is designed to cause the Moving Patient scheme to fail due to large differences in
the brain anatomy between patient and atlas in the tumor region. We demonstrate that the Moving Atlas
scheme retains good reconstruction quality for the tumor anatomy label, the tumor initial condition, and
the characteristic diffusivity of tumor cells, while the Moving Patient scheme falls short as it inverts tumor
growth in the ’wrong’ (atlas) geometry.
Setup. For both, atlas and patient, we generate a purely synthetic brain anatomy, composed of an
elliptical white matter inclusion surrounded by gray matter. The white matter inclusions for atlas and
14For our semi-synthetic test case setting, where the patient target data is generated from synthetic tumor progression simulation
in the healthy brain, the healthy patient brain is known and the approximation quality can be measured exactly.
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patient differ greatly in size. The target data cD are generated synthetically from a tumor-progression
simulation (with p = p?) using our reaction-diffusion model with ρ?f = 15 and k
?
f = 1E−2 from an initial
condition with two nearby Gaussians enabled in the patient geometry. The healthy atlas geometry is
depicted in the first row, the tumor bearing patient geometry in the last row of Fig. 4.1. We use the same
set of np = 343 Gaussians with standard deviation σ = 2pi/30 for the target data generation and inversion.
For simplicity, tumor growth is enabled only in white matter. We invert for the registration velocity v, the
parameters p for the tumor initial condition, and for the characteristic diffusivity k f in white matter.
Reconstruction using the Moving Atlas Scheme
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Reconstruction using the Moving Patient Scheme
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Quantitative Results
inv-k f ek f µB,L2 DICEB µB0,L2 DICEB0 µT,L2 DICET ec0,L2
MA 7.68E−3 2.32E−1 5.04E−2 9.98E−1 3.25E−2 9.98E−1 3.32E−2 9.89E−1 1.84E−1
MP 0.00 1.00E0 6.50E−2 9.95E−1 3.48E−2 9.96E−1 9.88E−1 0.00E0 1.00E0
Fig. 4.1: Results for SYN – Synthetic Brain (ground truth proliferation rate ρ f = 15 and diffusivity k f = 1E−2
in white matter, tumor growth disabled in gray matter). We compare the new Moving Atlas (MA) Picard scheme
(left tableau), and the Moving Patient (MP) scheme (right tableau). The figure shows anatomy and tumor labels
(from left to right: WM, GM, CSF, and TU), the residual differences (if available), and a hard segmentation based
on the given probabilities for the individual tissue classes. The synthetic healthy atlas and the patient are composed
of an elliptic inclusion of white matter in a gray matter rectangular brain (see text for details; axial-slice 64 of a
3D volume). We show the initial configuration for the problem (top row; iteration k = 1), two intermediate results
(second row; k = 2, and third row; k = 3), the final configuration after joint registration and tumor inversion (fourth
row; iteration k = 6) and the target patient data (reference image; bottom row). All results are presented in patient
space. In the table, we report the reconstructed diffusivity inv-k f and its relative error ek f with respect to the ground
truth, the average mismatch for the anatomy labels of the tumor bearing brain µB,L2 , for the healthy brain tissue
labels µB0,L2 and for the tumor µT,L2 , the mean Dice coefficients for brain tissue DICEB, for the healthy patient brain
tissue DICEB0 and for the tumor DICET . Furthermore, we measure the `2-error ec0,L2 of the reconstructed tumor
initial condition with respect to the ground truth.
Observation. In this case, the inclusions of white matter in atlas and patient vary significantly in size
(cf. Fig. 4.1). Thus, registering the atlas to the patient requires strong local expansion of volume. Looking
at Fig. 4.1 (right tableau), in the first iteration, to prevent the registration from directly matching the target
tumor unaided by the tumor solver, we choose a higher regularization parameter βv for the registration
problem. Therefore, warping the target tumor to the atlas space basically corresponds to a copy operation.
(before k = 2). This warped-to-atlas tumor is used for tumor inversion in the atlas space. The subsequent
registration step (with lower regularization) computes a velocity that registers the patient (small tumor in
large white matter blob) to the atlas (small tumor in small white matter blob). This results in a compression
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of the patient white matter, and consequently yields a very small target tumor for the inversion in the atlas
(k = 3).15 In subsequent iterations (with further reduced registration regularization), the warped-to-atlas
target tumor is compressed further, ultimately causing the Moving Patient scheme to fail and returning a
relative error of almost 100% for the reconstruction of the tumor label, the reconstruction of the tumor
initial condition, and the reconstruction of the characteristic diffusivity k f in white matter cf. Fig. 4.1).
The new Moving Atlas scheme, however, maintains a good reconstruction quality and results in only 3.3%
relative errors for the tumor label, 18.4% relative errors for the reconstruction of the tumor initial condition
and 23.2% relative error in the reconstruction of the characteristic diffusivity rate k f in white matter.
4.5. Results for STRV – Synthetic Tumor & Real Velocity. With the results for the STRV test cases,
we show the general applicability of the new registration and tumor inversion coupling scheme as well as
its improved properties in terms of correct reconstruction of initial tumor and healthy brain geometry. We
evaluate the Moving Atlas scheme for a real brain geometry with synthetically generated target tumor such
that the true tumor model parameters are known and we have access to the true healthy patient brain.
Purpose. With the STRV test case experiments, we pursue three main purposes: (i) We give experimen-
tal evidence for the convergence of the new Moving Atlas scheme for several settings; (ii) we compare our
coupled image registration and tumor inversion schemes Moving Patient and Moving Atlas to standalone
tumor inversion, replacing the missing second snapshot (healthy patient) by a statistical atlas without
involving image registration; (iii) we show the superiority of the new Moving Atlas scheme over the pre-
viously presented Moving Patient scheme in terms of reconstruction quality of the (initially unknown)
healthy patient brain anatomy and meaningful reconstruction of biophysical tumor-growth characteris-
tics, in particular shape and sparsity of the ground truth tumor initial condition and prediction of the
grown tumor.
Setup. For both atlas and patient, we use real brain MR imaging data from two (healthy) individuals.
The target tumor cD is generated synthetically from a tumor-progression simulation (with p = p?) using
our reaction-diffusion model. Accordingly, the ground truth velocity field is unknown (or may not even
exist due to a possibly wrong model), but the true tumor model parameters are known. We consider two
different tumor locations (STRV-C1) and (STRV-C2) and varying time horizons for the tumor-progression
simulation. An overview is given in Tab. 4.2. For (STRV-C1) we also employ different settings of the
parametrization of the tumor initial condition: For parameter setting #1, we use a set of np = 125 Gaussian
basis functions with standard deviation σ = 2pi/30, whereas, for settings #2 and #3, we use smaller (but
more; np = 343) Gaussians with σ = 2pi/64 to generate sparser ground truth initial conditions. The same
set of Gaussian basis functions is used for target data generation and inversion. The target data are
generated from a forward simulation with ρ?f = 15 and k
?
f = 1E−1 and an initial condition with two
nearby Gaussians enabled. For simplicity, tumor growth is enabled only in white matter. We invert for
the tumor initial condition and the characteristic diffusivity k f in white matter.
Table 4.2: STRV test case variations. Parameter choices for the synthetic tumor with real velocity (STRV) test
case; ground truth: (ρ?f = 15, ρ
?
1 = 1, ρ
?
1 = 0, k
?
f = 1.00E−1, k?1 = 1, k?1 = 0, p = p?). For the initial condition
parametrization, we use a regular grid of np = 125 (large σ), and np = 343 (small σ) Gaussian basis functions,
respectively with standard deviation σ as outlined below, and a spacing of δ = 1.5 σ. The grid is centered around
the positions xc1 = 2pi/128(39, 63, 64) (STRV-C1) and xc2 = 2pi/128(61, 89, 64) (STRV-C2), respectively (cf. Fig. 4.3
and Fig. 4.5 for the location of tumor seed).
test case setting #1 setting #2 setting #3
(STRV-C1) σ = 2pi/30, T = 0.16 σ = 2pi/64, T = 0.32 σ = 2pi/64, T = 0.44
(STRV-C2) σ = 2pi/64, T = 0.16 σ = 2pi/64, T = 0.32
Misfit and Gradient Reduction of the Moving Atlas Scheme. To experimentally assess convergence of
the Moving Atlas scheme over the Picard iterations, we report the `2-mismatch and Dice overlay coefficients
15Note, the displayed results are in the patient space, i.e., the inverse of the deformation is applied to display atlas labels in
patient space, and the very small reconstructed tumor in the atlas is expanded when warped to the patient space.
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Quantitative Results for the Moving Atlas Joint Inversion Scheme
It βv µB,L2 DICEB µB0,L2 DICEB0 µT,L2 DICET ‖g‖rel ec0,L2 Tit [s]
1 1E0 1.00E0 5.45E−1 6.77E−1 5.51E−1 1.00E0 0.00E0 1.00E0 1.00E0 5.64E2
2 1E−1 8.79E−1 5.80E−1 6.07E−1 5.93E−1 2.90E−1 7.92E−1 2.04E−2 4.25E−1 9.45E2
3 1E−2 6.54E−1 7.29E−1 4.51E−1 7.38E−1 2.04E−1 8.24E−1 1.45E−2 3.51E−1 8.44E2
4 1E−3 4.06E−1 8.66E−1 2.80E−1 8.72E−1 1.16E−1 8.80E−1 1.36E−2 2.08E−1 1.63E3
5 1E−4 2.62E−1 9.32E−1 1.81E−1 9.37E−1 7.57E−2 9.48E−1 7.01E−3 9.55E−2 8.46E2
6 1E−4 2.36E−1 9.42E−1 1.64E−1 9.46E−1 6.74E−2 9.51E−1 4.91E−3 5.75E−2 8.58E2
7 1E−4 2.33E−1 9.43E−1 1.62E−1 9.47E−1 6.49E−2 9.50E−1 4.15E−3 7.13E−2 5.69E3
Fig. 4.2: Misfit reduction of the new Moving Atlas (MA) Picard iteration scheme. We show qualitative and
quantitative results for the (STRV-C1) test case with parameter setting #1 from Tab. 4.2 over the course of the
Moving Atlas Picard-iteration-type solution scheme with a sparsity constraint on the initial condition for the
tumor inversion solver. We use the ground truth values ρ f = ρ?f = 15 and k f = k
?
f = 1E−1 in white matter for the
inversion. The figure shows anatomy labels of the healthy atlas brain and the patient brain with an (artificially) grown
tumor (see text for details; axial-slice 64 of a 3D volume). We show the initial configuration for the problem (top row;
iteration k = 1), an intermediate result (second row; k = 3), the final configuration after joint registration and tumor
inversion (third row; iteration k = 7), and the target patient data (reference image; bottom row). Each row contains
(from left to right) the anatomy labels for WM, GM, CSF, and TU, the residual differences (if available) between the
anatomy labels, and a hard segmentation based on the given probabilities for the individual tissue classes. In the
table, we report the average mismatch for the anatomy labels for the pathologic brain tissue labels µB,L2 , the healthy
brain tissue labels µB0,L2 and the tumor µT,L2 , the mean Dice coefficient for brain tissue DICEB, healthy patient
brain tissue DICEB0 and tumor DICET over the Picard iterations. Furthermore, we measure the `2-error ec0,L2
of the reconstructed tumor initial condition to the ground truth, and the relative norm ‖g‖rel of the approximated
reduced gradient of the coupled formulation. Timings per iteration are given in seconds for parallel execution using
64 MPI tasks on three nodes of HazelHen. The last row shows the final values for mismatch and Dice as well as the
time-to-solution (accumulated runtime) in seconds.
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Table 4.3: Comparison of the tumor inversion standalone (T) solver only (w/o inter-subject registration), the
Moving Patient (MP) Picard iteration scheme, and the new Moving Atlas (MA) Picard iteration scheme. We
show quantitative results for the (STRV-C1) and (STRV-C2) test cases with centers xc1 and xc2 , and parameter
setting #1 from Tab. 4.2, respectively. We invert for the registration velocity v, the parameters p of the tumor initial
condition, and for the characteristic diffusivity k f in white matter. We set the proliferation rate to the true value
ρ f = 15. We report the reconstructed diffusivity inv-k f and its relative error ek f with respect to the ground truth,
the average mismatch for the anatomy labels for the pathologic brain tissue labels µB,L2 , the healthy brain tissue labels
µB0,L2 and the tumor µT,L2 , the mean Dice coefficients for brain tissue DICEB, for the healthy patient brain tissue
DICEB0 and for the tumor DICET . We also measure the `2-error ec0,L2 of the reconstructed tumor initial condition
to the ground truth. Timings are given for parallel execution using 64 MPI tasks on three nodes of HazelHen.
ID center setting solver inv-k f ek f µB,L2 DICEB µB0,L2 DICEB0 µT,L2 DICET ec0,L2 T
it [s] Ttuinv [s] T
reg
inv [s]
#1
C1 #1
T 1.15E−1 1.50E−1 N/A N/A N/A N/A 2.90E−1 7.92E−1 4.25E−1 N/A – N/A
#2 MP 9.22E−2 7.80E−2 3.72E−1 8.72E−1 2.56E−1 8.79E−1 1.44E−1 9.25E−1 3.25E−1 5.72E3 1.99E3 7.88E2
#3 MA 9.05E−2 9.50E−2 2.33E−1 9.43E−1 1.62E−1 9.47E−1 6.49E−2 9.50E−1 7.13E−2 5.69E3 1.59E3 1.14E3
#4
C2 #1
T 1.48E−1 4.80E−1 N/A N/A N/A N/A 2.93E−1 5.54E−1 4.08E−1 N/A – N/A
#5 MP 8.86E−2 1.14E−1 3.76E−1 8.79E−1 2.55E−1 8.80E−1 1.90E−1 7.96E−1 4.70E−1 6.05E3 2.50E3 7.49E2
#6 MA 9.23E−2 7.70E−2 2.37E−1 9.48E−1 1.60E−1 9.48E−1 6.07E−2 9.70E−1 6.33E−2 7.89E3 4.40E3 9.26E2
for the reconstruction of the (pathologic) brain anatomy (µB,L2 and DICEB), the healthy patient anatomy
(µB0,L2 and DICEB0 ), and the reconstructed (grown) tumor (µT,L2 and DICET) in Fig. 4.2 for the (STRV-C1)
test case. Furthermore, we monitor the `2-error ec0,L2 for the reconstructed tumor initial condition with
respect to the ground truth and the relative norm ‖g‖rel of the (approximated) reduced gradient of the
coupled formulation (2.2).
Observations. Fig. 4.2 shows a monotonic reduction of data-misfit values and the corresponding gain
in tissue overlay Dice scores for the brain anatomy, the healthy patient anatomy, the grown tumor, and
the initial tumor condition. Although we do not have a proof for the convergence of the Moving At-
las Picard-iteration-type solution strategy (outlined in §2.2), we monitor the relative norm ‖g‖rel of the
(approximated) reduced gradient for the Moving Atlas formulation (2.2), indicating convergence to an
optimum. The norm of the approximated gradient continually decreases throughout our Picard-iteration-
type solution strategy. Our solution scheme, and hence the gradient, neglect the term ∂mP(1)Φ(p)α(0)
in (2.6h). This term, however, becomes very small as the misfit and, thus, α(0) decrease.
Standalone Tumor Inversion versus Moving Patient versus Moving Atlas. To compare the different
inversion schemes, we show results obtained using the newly introduced Moving Atlas (MA) strategy
to the results for the Moving Patient (MP) solution scheme and those for a tumor standalone (T) solver
without inter-subject registration, respectively, in Tab. 4.3 for both test cases (STRV-C1) and (STRV-C2).
Observations. Solving the single-snapshot tumor inversion problem without inter-subject registration
using a tumor standalone solver for some arbitrary normal brain anatomy (atlas) (cf. [10]) exhibits poor
reconstruction quality. Our joint registration and biophysical inversion Moving Atlas approach (run #3 and
#6 in Tab. 4.3) results in significantly higher reconstruction quality and outperforms the other strategies
(Moving Patient, run #2 and #5, and tumor standalone, run #1 and #4) by a large margin, both in terms of
data-misfit and Dice coefficient, as well as in reconstructing the true initial condition.
Comparing against the tumor standalone approach, we improve the reconstruction quality of the
input data (grown tumor) from a relative data-misfit of 2.90E−1 (run #1) to 6.49E−2 (run #3) using the
new Moving Atlas joint inversion scheme, and likewise improve the reconstruction quality for the tumor
initial condition (compared to the ground truth) from a relative `2−error of 4.25E−1 for tumor standalone
(run #1) to 7.13E−2 (run #3) for the Moving Atlas scheme. Furthermore, the estimation of the characteristic
diffusivity in white matter k f is significantly improved for the joint inversion scheme (going from a relative
error of 4.80E−1 (tumor standalone; run #4) to a relative error of 7.70E−2 (Moving Atlas; run #6)).
Moving Patient versus Moving Atlas. For a more detailed comparison of the Moving Atlas and the
Moving Patient scheme, we show qualitative results of the reconstructed tumor initial condition and the
grown tumor compared to the target data and ground truth initial condition in Fig. 4.3 (for STRV-C1)
and Fig. 4.5 for (STRV-C2). In Fig. 4.6, we outline the initial and final residuals for the different brain tissue
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Moving-Atlas Moving-Patient
(#2: T = 0.32, r = 15, k f = 0.1, s = 2p/64)
ATRV-C1: Target Data and Ground Truth
Moving-Atlas Moving-Patient
(#1: T = 0.16, r = 15, k f = 0.1, s = 2p/30)
ATRV-C1: Target Data and Ground Truth
Fig. 4.3: Comparison of the Moving Patient (MP), and the new Moving Atlas (MA) scheme. We show quali-
tative results for the (STRV-C1) test case with parameter setting #1 from Tab. 4.2 (left), and parameter setting #2
from Tab. 4.2 (right). The image shows the reconstructed grown tumor and tumor initial condition for the Moving
Atlas and Moving Patient solution scheme, featuring different time horizons and sparsity of the initial condition.
We show parts of the patient brain anatomy with the respective reconstructed tumor initial condition (magenta
wireframe/volume) as compared to the ground truth initial condition (cyan volume). The grown tumor is indicated
as white wireframe (3D cut image), and as blue semi-transparent volume compared to the target data given as red
wireframe (close-up image). The top row shows the test case target data (grown tumor; white wireframe) and initial
condition ground truth (cyan volume) for each set of parameters. The close-up image shows a volume rendering of
the grown tumor, overlaid with a wireframe indicating the boundary of the tumor resulting from the segmentation
(used for visualization purposes). The light blue/white area indicates the ventricles with CSF.
labels (white matter (WM), gray matter (GM), cerebrospinal fluid (CSF), grown tumor (TU(t = 1)), and
tumor initial condition TU(t = 0); for axial slice 64 of a 3D-volume) before and after the joint registration
and biophysical inversion for the test case variants (STRV-C1) and (STRV-C2). Furthermore, we display
structural differences between the utilized normal brain anatomies for both inversion schemes. We show
qualitative results for a longer time horizon of tumor evolution for the (STRV-C1) test case (with a very
sparse initial condition) in Fig. 4.4.
We also study the sensitivity of the Moving Atlas and Moving Patient solution strategies with respect to
perturbations in the tumor model parameters. In Tab. 4.4, we vary the value of the characteristic diffusivity
in white matter from the ground truth, and monitor the obtained reconstruction performance.
Observations. The new Moving Atlas scheme outperforms the Moving Patient counterpart [49] in various
ways. Tab. 4.3 shows that, for the reconstruction of the brain anatomy (model prediction for anatomy
labels of brain tissue labels WM, GM, and CSF), we reach a relative data-misfit (`2-error) of 2.33E−1 (run
#3) compared to 3.72E−1 (run #2) for the Moving Patient scheme (this translates to a Dice score of 9.43E−1
(averaged over all labels) for the Moving Atlas compared to a Dice score of 8.72E−1 for the old scheme).
Similarly, for the approximation of the actual healthy patient anatomy, we improve from a Dice score of
8.79E−1 (relative `2-error of 25.6%; run #3) obtained from the Moving Patient solution to a Dice score of
9.47E−1 (relative `2-error of only 16.2%; run #2) using the new scheme. Fig. 4.6 illustrates the structural
differences between the atlas and patient brain, the initial residuals and the residuals after joint inversion
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Fig. 4.4: Comparison of the Moving Patient (MP), and
the new Moving Atlas scheme. We show qualitative
results for the (STRV-C1) test case with parameter set-
ting #3 from Tab. 4.2. The image shows the reconstructed
grown tumor and the tumor initial condition for the Mov-
ing Atlas and Moving Patient solution scheme. The
images show parts of the patient brain anatomy and illus-
trate the respective reconstructed tumor initial condition
(magenta wireframe/volume) as compared to the ground
truth initial condition (cyan volume). The grown tumor
is indicated as white wireframe (bottom row), and as blue
semi-transparent volume compared to the target data given
as red wireframe (top row). The light blue/white area in-
dicates the ventricles with CSF. The top row shows the
test case target data (grown tumor; white wireframe) and
initial condition ground truth (cyan volume). The close-
up image shows a volume rendering of the grown tumor,
overlaid with a wireframe indicating the boundary of the
tumor resulting from the segmentation (used for visual-
ization purposes). We observe that the Moving Patient
reconstruction yields a wrong position of the initial condi-
tion and inferior reconstruction of the grown tumor.
(#3: T = 0.44, r = 15, k f = 0.1, s = 2p/64)
ATRV-C1: Target Data and Ground Truth
Moving-Atlas Moving-Patient
using the Moving Atlas and the Moving Patient scheme, respectively, for an exemplary slice (axial slice
64) of the 3D volume. We observe smaller errors for the Moving Atlas solution. The improved anatomy
reconstruction is characteristic for the Moving Atlas strategy; we observe similar trends for various solver
and parameter configurations (compare also Tab. 4.4 with inversion under perturbed or wrong tumor
model parameters).
The Moving Atlas scheme furthermore results in improved reconstruction quality of the predicted
grown tumor and higher similarity to the target data. For (STRV-C1), the Moving Atlas scheme results in a
relative error of 6.4% (Dice score of 9.50E−1; run #3) compared to a relative error of 14.4% (Dice score of
9.25E−1; run #2) for the Moving Patient solution. The numbers for (STRV-C2) are very similar with 6.0%
relative error (Dice score of 9.70E−1; run #6) versus 19.0% relative error (Dice score of 7.96E−1; run #5).
The primary objective for the derivation of the Moving Atlas scheme was to allow for a more informa-
tive inversion for biophysical model parameters. We primarily consider the estimation of the tumor initial
condition, but also invert for the characteristic diffusivity k f in white matter. The relative errors16 ec0,L2 for
the inversion of the ground truth tumor initial condition in Tab. 4.3 obtained for each scheme clearly attest
the Moving Atlas scheme to be more reliable and sound in recovering biophysical parameters17. Using
the improved Moving Atlas scheme, we achieve excellent reconstruction of the true initial condition with
a relative error of only 7.1% (for (STRV-C1); run #3) and 6.3% (for (STRV-C2); run #6), as opposed to a
relative error of 32.5% (for (STRV-C1); run #2) and 42.4% (for (STRV-C2); run #5), respectively, when using
the Moving Patient scheme instead. An illustration of the error is given in Fig. 4.6 (for an axial cut at slice
64). We explain the improved inversion properties of the Moving Atlas scheme by its general idea to seek
for a good approximation of the healthy patient brain anatomy first, and, thus, to carry out the inversion
in the “correct” space. For the Moving Patient scheme, the inversion in the “wrong” anatomy (atlas space)
16Note, that for the Moving Atlas scheme, the reconstructed initial condition naturally “lives” in the patient space; for the Moving
Patient solution strategy, we invert for the tumor initial condition in the atlas space. For a fair comparison, the reconstructed initial
condition for the Moving Patient scheme is advected to the patient space before computing the relative error to the ground truth.
17Our analysis assumes that tumor-growth is perfectly described by a reaction-diffusion model, which is quite certainly not true.
When we say “biophysically meaningful” this is to be seen under the aforementioned assumption. Note furhermore, that the tumor
model can easily be exchanged in the modular setting of our Picard iteration approach.
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Table 4.4: Comparison of the Moving Patient, and the new Moving Atlas scheme. We report results for the
(STRV-C1) and (STRV-C2) test cases with centers xc1 and xc2 , and parameter setting #1 from Tab. 4.2, respectively.
Here we are not inverting for k f , but only invert for the tumor initial condition and registration velocity. We analyze
the sensitivity of the joint inversion with respect to perturbations in the characteristic diffusivity k f by inverting
with different choices of k f ; bold numbers correspond to inversion with the ground truth value (k?f = 1E−1). We
always use the ground truth proliferation rate ρ f = 15. We report the average mismatch for the anatomy labels
for the pathologic brain tissue labels µB,L2 , the healthy brain tissue labels µB0,L2 and the tumor µT,L2 , the mean
Dice coefficient for brain tissue DICEB, for the healthy patient brain tissue DICEB0 and for the tumor DICET (in
cases without Dice score for the tumor reconstruction, the tumor probability map has values below 0.5 everywhere).
Furthermore, we measure the `2-error ec0,L2 of the reconstructed tumor initial condition to the ground truth.
ID k f µB,L2 DICEB µB0,L2 DICEB0 µT,L2 DICET ec0,L2
#7
ST
R
V
-C
1
(#
1) M
P
5E−1 3.80E−1 8.62E−1 2.58E−1 8.79E−1 3.96E−1 – 4.99E−1
#8 3E−1 3.76E−1 8.64E−1 2.57E−1 8.79E−1 2.88E−1 7.76E−1 8.68E−1
#9 k?f = 1E−1 3.72E−1 8.72E−1 2.56E−1 8.79E−1 1.45E−1 9.21E−1 3.23E−1
#10 1E−3 3.73E−1 8.75E−1 2.59E−1 8.73E−1 2.49E−1 8.75E−1 5.39E−1
#11
M
A
5E−1 2.40E−1 9.46E−1 1.62E−1 9.47E−1 5.65E−1 – 1.37E0
#12 3E−1 2.40E−1 9.37E−1 1.63E−1 9.48E−1 2.86E−1 3.66E−1 9.41E−1
#13 k?f = 1E−1 2.35E−1 9.43E−1 1.62E−1 9.48E−1 6.77E−2 9.56E−1 8.02E−2
#14 1E−3 2.37E−1 9.48E−1 1.61E−1 9.48E−1 5.40E−1 – 7.04E−1
#15
ST
R
V
-C
2
(#
1) M
P
3E−1 3.76E−1 8.79E−1 2.55E−1 8.80E−1 3.66E−1 – 4.96E−1
#16 2E−1 3.76E−1 8.79E−1 2.55E−1 8.80E−1 2.64E−1 – 5.25E−1
#17 k?f = 1E−1 3.76E−1 8.80E−1 2.55E−1 8.80E−1 1.93E−1 8.34E−1 4.24E−1
#18 1E−2 3.82E−1 8.75E−1 2.59E−1 8.75E−1 2.57E−1 6.86E−1 6.94E−1
#19
M
A
3E−1 2.41E−1 9.46E−1 1.63E−1 9.47E−1 4.20E−1 – 5.99E−1
#20 2E−1 2.40E−1 9.46E−1 1.62E−1 9.47E−1 2.54E−1 – 7.96E−1
#21 k?f = 1E−1 2.37E−1 9.48E−1 1.60E−1 9.48E−1 6.07E−2 9.70E−1 6.33E−2
#22 1E−2 2.40E−1 9.46E−1 1.62E−1 9.47E−1 3.39E−1 6.21E−1 6.78E−1
has the potential to induce large errors for the estimation of biophysical parameters as shown in §4.4 since
the inter-subject deformation map can aid matching the pathologic brains. In particular, there is no impli-
cation that this deformation map produces reasonable results when applied to the tumor initial condition
(or other quantities that describe the time point of tumor genesis) in order to translate the latter into the
individual patient application space. Visual inspection of our simulation results for longer time horizons
in Fig. 4.4 support this point: The Moving Patient solution recovers a wrong position of the tumor initial
condition (compare the green (ground truth) and purple (reconstruction) iso-volume representations of
the initial tumor condition. A wrong position, wrong shape, or wrong sparsity of the initial condition
can, in a second step, also cause a wrong estimation of the characteristic proliferation rate or tumor cell
infiltration rate. For our experiments, the difference for the estimation of the characteristic diffusivity k f
is, however, not significant; both schemes yield comparable results. One possible reason for this could
be that the diffusion part of the gradient initially is large but then flattens out compared to the gradient
component for the initial condition parametrization. The theoretical and numerical analysis of this effect
is ongoing work.
5. Conclusion. We present a new inverse problem formulation to solve the patient-specific tumor
inversion problem given a single data-snapshot in time only. We remedy the lack of healthy patient
imaging data via registration to a healthy atlas brain, resulting in a joint inter-subject registration and
biophysical inversion scheme. We simultaneously solve for an estimation of the inter-subject deformation
map, and (a subset of) the biophysical model parameters for tumor progression. More specifically, we
solve for an estimation of a sparse tumor initial condition, and for the characteristic diffusivity rate of
tumor cells in white matter. The presented scheme conceptually improves on our earlier coupled solution
approach [49]. The latter uses the registration to warp patient target data towards the atlas space, and
inverts for tumor model parameters in the atlas brain (proxy for the unknown healthy patient brain). This
may introduce large errors due to unwanted data fitting and model inversion in a wrong anatomy. We
demonstrate this for synthetic cases. The new scheme computes an approximation of the healthy patient
and performs the tumor inversion in the partient space. We furthermore encourage a sparse localization
of the initial tumor (presented in our work [52]) to allow for a more reliable reconstruction of the model
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Moving-Atlas Moving-Patient
(#2: T = 0.32, r = 15, k f = 0.1, s = 2p/64)
ATRV-C2: Target Data and Ground Truth
Moving-Atlas Moving-Patient
(#1: T = 0.16, r = 15, k f = 0.1, s = 2p/64)
ATRV-C2: Target Data and Ground Truth
Fig. 4.5: Comparison of the Moving Patient, and the new Moving Atlas scheme. We show qualitative results for
the (STRV-C2) test case with parameter setting #1 from Tab. 4.2 (left image), and parameter setting #2 from Tab. 4.2
(right image). The image shows the reconstructed grown tumor and the tumor initial condition for the Moving
Atlas and Moving Patient solution scheme featuring different time horizons for the tumor evolution. Illustrated
are parts of the (approximated) patient brain anatomy with the respective reconstructed tumor initial condition
(magenta wireframe/volume) as compared to the ground truth initial condition (cyan volume). The grown tumor
is indicated as white wireframe (bottom images), and as blue semi-transparent volume compared to the target data
given as red wireframe (top images). The first row shows the test case target data (grown tumor; white wireframe
(left) and volume rendering (right)) and initial condition ground truth (cyan volume) for each set of parameters.
parameters. This biophysically motivated constraint can help to understand tumor genesis and its role
in the subsequent tumor evolution. We derive a Picard-iteration-type solution strategy by dividing the
strongly coupled set of first order optimality conditions into two solvers.
For our new method, we observe (i) improved similarity of the reconstructed probability maps of
brain tissue labels (WM, GM, CSF) with respect to the patient data, (ii) significantly smaller errors for the
reconstruction of the grown tumor, (iii) a better approximation of the actual healthy patient brain anatomy,
and, (iv) more reliable reconstruction of biophysical parameters, such as the tumor initial condition.
The reconstruction result obtained from the Moving Atlas scheme seems to be more “natural” as we
invert in the “correct” brain anatomy of the (healthy) patient, and the registration does not act on the
tumor probability map (as is the case for the Moving Patient strategy). In particular, using the Moving
Atlas scheme, we were able to improve the Dice score for the brain anatomy from 8.72E−1 for the Moving
Patient strategy to 9.43E−1; the Dice score for the approximation of the healthy patient brain anatomy
from 8.79E−1 for Moving Patient to 9.47E−1; and the Dice coefficient for the tumor reconstruction from
8.34E−1 for Moving Patient to 9.70E−1. We observe an excellent reconstruction of the true initial condition
with a relative error of only 7.1% (STRV-C1) and 6.3% (STRV-C2) (compared to 32.3% and 42.4% for
Moving Patient) using the more sophisticated Moving Atlas scheme. We further conclude, that a sparse
localization of the initial condition is essential if targeting biophysical parameter estimation from patient
MRI. The previously used `2-regularization results in rich initial conditions. Lastly, the Moving Atlas
solution scheme seems to be more useful in identifying wrong parameters (such as cell proliferation rate
and cell migration rate of brain tissue) than the Moving Patient counterpart.
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Residuals after Reconstruction using the Moving Atlas and Moving Patient Scheme for (STRV-C2)
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Fig. 4.6: Comparison of the Moving Patient Picard iteration scheme, and the new Moving Atlas Picard iteration
scheme. We show initial and final residuals for the (STRV-C1) test case (top) and the (STRV-C2) test case (bottom)
with parameter setting #1 from Tab. 4.2, respectively. The tableaus show the initial and final residual for the
reconstruction of the pathologic and healthy patient for the Moving Atlas and Moving Patient solution scheme,
respectively for parameter setting #1 from Tab. 4.2 for both tumor seeds xc1 and xc2 . For each case, the top row shows
the initial residual between patient input data and the healthy atlas anatomy; the healthy anatomies are illustrated
on the right, where gray indicates white matter, blue indicates gray matter, and black indicates cerebrospinal fluid
with ventricles. The final residual for the reconstruction of the patient input data and the healthy patient anatomy
are shown in the second and third row, for joint inversion using the Moving Patient (run #2 for (STRV-C1) and
run #5 for (STRV-C2) in Tab. 4.3) and the Moving Atlas scheme (run #3 for (STRV-C1) and run #6 for (STRV-C2)
in Tab. 4.3), respectively. All images show axial slice 64 (of 128) of the 3D volume.
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